Reproductive function in teenage and young adult cancer survivors

Not Applicable

• Conditions: Cancer; Cancer and reproductive health

• Registration Number: ISRCTN12061770
• Lead Sponsor: niversity of Edinburgh and NHS Lothian

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-03-03
• Last Update Posted: 13 March 2023
• Study Completion: 2027-01-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1. Willing and able to provide written informed consent (including by parent/guardian where appropriate).
2. Aged 13-25 years old
3. First cancer diagnosis
4. Requires cancer treatment (surgery, chemotherapy including targeted therapies, radiotherapy, bone marrow transplant).

Exclusion Criteria

1. Inability to provide informed consent
2. Does not require cancer treatment
3. Where treatment is not given with the intention of cure or long-term survival

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of reproductive failure and of gonadal dysfunction measured using diagnosis/treatment regimen at 2 years after diagnosis

Secondary Outcome Measures

Name	Time	Method
ptake of fertility preservation services, and long-term reproductive outcomes including ongoing ovulation/spermatogenesis, conception, age at menopause, and the need for hormone replacement. The prevalence of reproductive failure and of gonadal dysfunction by diagnosis/treatment regimen at 1 and 3 years after diagnosis. A blood sample is collected at baseline, and 1-, 2- and 3-year follow-up. In females, anti-Mullerian hormone (AMH) levels will be measured in serum, data will be analysed in conjunction with follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) levels. For males, Inhibin B will be measured in serum. Inhibin B data will be analysed in conjunction with FSH/LH/testosterone levels.